Two kinds of oral hypoglycemic compound preparations have entered the country one after another! There are many new drug approval highlights in the near future

Last week, four new class 1 drugs were approved for clinical use: sh229 tablets, InBev sodium tablets, shenggliptin phosphate tablets and zsp1602 capsules AstraZeneca's salgretine metformin sustained-release tablets have also been reviewed and will be imported into China Point 1 after gligligliptin and metformin tablets of bringlingham, the review of the application for import and marketing of aslikonaxagliptin and metformin sustained-release tablets has also been completed Like gliptin and metformin tablets, three kinds of fixed agent quantities have also been declared for the sustained-release tablets of saggliptin and metformin It is speculated that only two fixed specifications may be approved in the end Two kinds of oral antidiabetic compound preparations have entered China one after another Let's see the later market situation Point 2 sh229, a class 1 new drug of Nanjing Shenghe, was approved for clinical use This product was undertaken in December 2016 In the 13th batch of "publicity of drug registration application to be included in the priority review process", it is a direct antiviral drug for the treatment of hepatitis C In addition, since 2017, Nanjing Shenghe has also submitted class 1 new drugs, namely sh526 tablets Point 3: yinglaibuwei sodium, a class 1 new drug of Guangdong dongyangguang, was approved for clinical use This product was undertaken in December 2016 In the fourteenth batch of "publicity of drug registration application to be included in the priority review procedure", it is also a direct antiviral drug for the treatment of hepatitis C In addition, dongyangguang has applied for many 1 (1.1) new drugs in recent years The specific list is as follows: see 4 Shengshi Tyco's 1 new drug, shenggliptin phosphate tablet, which was approved for clinical use This product was undertaken in October 2016 for the treatment of type 2 diabetes At present, the clinical DPP4 inhibitors in China include retagliptin of Hengrui, yougliptin tablets of Chengdu Yuandong, fugliptin capsules of Chongqing fuchuang, eggliptin tablets of Shandong green leaves, and eggliptin tablets of Shandong xuanzhu At present, only Nanjing chang'ao's ogletin tablets and Jiangsu Haosen's begletin tablets have not been found in the CDE registration platform, for some reasons But last week, there was another clinical approval of "statins" Let's do it together Point 5: zsp1602 capsule, a new class 1 drug of Guangdong Zhongsheng, was approved for clinical use It was undertaken in October 2016 It is a class 1 innovative drug for the treatment of small cell lung cancer and other malignant tumors, with specifications of 10mg and 50mg Currently, only zsp1602 capsule has been approved for clinical use We are looking forward to the approval of another two drugs Point 6 Bayer pharmaceutical submitted the clinical application of rivaroxaban granules, acceptance No jxhl1700086, registration classification 2.2, which are not listed at home and abroad Rivaroxaban tablets were first imported from Bayer in 2009, and were used in adult patients undergoing selective hip or knee arthroplasty to prevent venous thrombosis From the date of listing to 2016, the sales volume of rivaroxaban rose all the way By 2016, its sales volume in sample hospitals had exceeded 250 million yuan.